SCHEMBL48894

SCHEMBL48894

c1ccc(-c2cncs2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.55
KDR P35968 1/20 0.49
DYRK2 Q92630 1/20 0.49
DYRK1B Q9Y463 1/20 0.49
PIM1 P11309 1/20 0.47
CD38 P28907 5/20 0.45
HDAC4 P56524 1/20 0.43
ESR1 P03372 2/20 0.42
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TBXAS1 P24557 1/20 0.41
ATM Q13315 1/20 0.41
MAPT P10636 1/20 0.39
IDO1 P14902 1/20 0.39
LRRK2 Q5S007 1/20 0.39
NOTUM Q6P988 1/20 0.39
KCNA5 P22460 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL28177501 0.98 DYRK1A (0.53) DYRK1AKDRDYRK2DYRK1BPIM1
SCHEMBL24271909 0.90 KDR (0.54) DYRK1AKDRDYRK2DYRK1BPIM1
SCHEMBL11691085 0.88 DYRK1A (0.46) DYRK1AKDRDYRK2DYRK1BPIM1
SCHEMBL16159852 0.87 PIM1 (0.47) DYRK1AKDRDYRK2DYRK1BPIM1
SCHEMBL16159544 0.85 KDR (0.50) DYRK1AKDRDYRK2DYRK1BPIM1
SCHEMBL8686043 0.83
SCHEMBL16159847 0.83 DYRK1A (0.45) DYRK1AKDRDYRK2DYRK1BPIM1
SCHEMBL16159268 0.83 DYRK1A (0.45) DYRK1AKDRDYRK2DYRK1BPIM1
SCHEMBL16159722 0.82 CD38 (0.48) DYRK1AKDRDYRK2DYRK1BPIM1
SCHEMBL8770678 0.82 DYRK1A (0.42) DYRK1AKDRDYRK2DYRK1BPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 779 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024103023-A2 12-LIPOXYGENASE INHIBITORS FOR THE TREATMENT OF LUPUS VERALOX THERAPEUTICS (US) 2024-05-16 WO claimed
WO-2024019959-A1 COMPOSITIONS FOR MODULATING LIPOXYGENASE AND METHODS OF USING SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-01-25 WO claimed
EP-3054936-B1 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS EASTERN VIRGINIA MEDICAL SCHOOL (US) 2023-10-18 EP claimed
CN-108017742-B Preparation method of oligomeric isobutene for synthesizing squalane 万华化学集团股份有限公司 2020-05-08 CN claimed
CN-108017742-A A kind of preparation method for the oligomerising isobutene for being used to synthesize saualane 万华化学集团股份有限公司 2018-05-11 CN claimed
US-20170095483-A1 DGAT1 INHIBITION FOR TREATMENT OF DEMYELINATING INFLAMMATORY DISEASE THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2017-04-06 US claimed
CN-103965136-B A kind of method preparing N-methylthiazoline-2-ketone compounds 苏州波菲特新材料科技有限公司 2016-09-07 CN claimed
WO-2015187704-A1 DGAT1 INHIBITION FOR TREATMENT OF DEMYELINATING INFLAMMATORY DISEASE THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-12-10 WO claimed
CN-103965136-A Method for preparing N-Methylthiazoline-2-ketone compound SUZHOU BOFEITE NEW MATERIALS TECHNOLOGY CO LTD 2014-08-06 CN claimed
US-8163900-B2 Seven-membered heterocyclic carbenes and their metal complexes WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2012-04-24 US claimed
US-5142545-A LASER DYE LAMBDA PHYSIK GESELLSCHAFT ZUR HERSTELLUNG VON LASERN MBH (DE) 1992-08-25 US claimed
US-4891305-A LASERS RICOH CO., LTD. (JP) 1990-01-02 US claimed
US-4418070-A 5-PHENYL-THIAZOLES MEIJI SEIKA KABUSHIKI KAISHA (JP) 1983-11-29 US claimed
US-4102688-A CONTAINING PYRAZOLO(3,4-B)PYRIDINE/3,6-DIONE MOIETY FUJI PHOTO FILM CO., LTD. (JP) 1978-07-25 US claimed
US-3970461-A Fogged, direct-positive silver halide emulsion containing carbocyanine dye having indolenine nucleus FUJI PHOTO FILM CO., LTD. (JA) 1976-07-20 US claimed
JP-57134417-A None JP disclosed
US-12544362-B2 Methods of treating acute respiratory distress syndrome with activators of Tie-2 EyePoint Pharmaceuticals, Inc. (US) 2026-02-10 US disclosed
US-3936308-A Photographic emulsions containing methine dyes having a 1H-imidazo[4,5-b]pyrazine nucleus EASTMAN KODAK COMPANY (US) 1976-02-03 US disclosed
US-3935010-A IMIDAZOQUINOXALINE DESENSITIZER EASTMAN KODAK COMPANY (US) 1976-01-27 US disclosed
US-3933507-A LIGHT INSENSITIVE SILVER SALT, POLYMETHINE SENSITIZER AGFA-GEVAERT, A.G. (DT) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12544362-B2 Methods of treating acute respiratory distress syndrome with activators of Tie-2 TIE1, ACE2, TEK DYRK1A 746/4885KDR 12/4885DYRK2 530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.